Puberty Blocker Trial: A Step Towards Evidence-Based Care

The Pathways Trial: A Landmark Study

The Pathways clinical trial, led by researchers at King’s College London (KCL), aims to shed light on the impact of puberty blockers on gender-questioning youth. This trial comes in response to a 2024 review by Dr. Hilary Cass, which highlighted the need for more robust evidence regarding the use of these drugs.

Addressing the Evidence Gap

Dr. Cass’s review revealed a lack of strong evidence supporting the use of puberty blockers in gender care for under-18s. This prompted the government to ban their prescription in the UK for this age group, both privately and through the NHS.

However, Dr. Cass emphasizes that the risks and benefits of these drugs are still not fully understood. She believes the trial is essential to gather the necessary evidence, stating, “We genuinely don’t know if there are harms.”

Ensuring Participant Safety

The trial has implemented enhanced safeguards to protect participants. These include a minimum age requirement and close monitoring of physical, social, and emotional well-being. The researchers will also assess the drugs’ effects on bone density, brain function, and fertility.

Dr. Cass argues that without the trial, young people may resort to unregulated sources for these drugs, which could pose greater risks. She highlights the need for evidence-based care to support this vulnerable group.

Navigating the Debate

The trial has faced opposition from campaigners and politicians, who argue that children cannot provide informed consent and that the drugs could cause irreversible harm. However, the researchers have carefully considered these concerns and adjusted the trial’s parameters accordingly.

The Bayswater Support Group, one of the campaigners taking legal action, believes the trial won’t resolve questions about puberty blockers. Meanwhile, TransActual, a trans campaign group, welcomes the trial but calls for a reversal of the puberty blocker ban, advocating for informed consent in gender care.

As the trial moves forward, it aims to provide much-needed clarity in this complex and sensitive area of healthcare.